Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease | Zendy

Michael Megaly | Zendy; Marwan Saad | Zendy; Emmanouil S. Brilakis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease

Author(s) -

Michael Megaly,

Marwan Saad,

Emmanouil S. Brilakis

Publication year - 2019

Publication title -

us cardiology review

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.148

H-Index - 3

eISSN - 1758-390X

pISSN - 1758-3896

DOI - 10.15420/usc.2019.4.1

Subject(s) - restenosis , medicine , percutaneous coronary intervention , coronary artery disease , cardiology , drug , artery , percutaneous , coronary arteries , stent , myocardial infarction , pharmacology

Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research